AS­CO17: As­traZeneca pumps up ex­pec­ta­tions on near-term can­cer drug wins, look­ing to shed a rep for fail­ure

CHICA­GO — As­traZeneca’s R&D team ar­rived at AS­CO on a crit­i­cal mis­sion.

With its lead­ing PARP in­hibitor outscor­ing chemo in treat­ing breast can­cer, mak­ing the spot­light …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER